45 results on '"Ardanaz M"'
Search Results
2. Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry
- Author
-
Bernal, T, Martínez-Camblor, P, Sánchez-García, J, de Paz, R, Luño, E, Nomdedeu, B, Ardanaz, M T, Pedro, C, Amigo, M L, Xicoy, B, del Cañizo, C, Tormo, M, Bargay, J, Valcárcel, D, Brunet, S, Benlloch, L, and Sanz, G
- Published
- 2015
- Full Text
- View/download PDF
3. The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome
- Author
-
Cordoba, I., Gonzalez-Porras, J.R., Such, E., Nomdedeu, B., Luño, E., de Paz, R., Carbonell, F., Vallespi, T., Ardanaz, M., Ramos, F., Marco, V., Bonanad, S., Sanchez-Barba, M., Costa, D., Bernal, T., Sanz, G.F., and Cañizo, M.C.
- Published
- 2012
- Full Text
- View/download PDF
4. Refractory anemia with ringed sideroblasts associated with thrombocytosis: comparative analysis of marked with non-marked thrombocytosis, and relationship with JAK2 V617F mutational status
- Author
-
Raya, J. M., Arenillas, L., Domingo, A., Bellosillo, B., Gutiérrez, G., Luño, E., Piñán, M. A., Barbón, M., Pérez-Sirvent, M. L., Muruzábal, M. J., Yánez, L., García, L., Lemes, A., Navarro, J. T., Elosegi, A., Cortés, M. A., Villegas, A., Durán, M. A., Ardanaz, M., Florensa, L., and On behalf of the Grupo Español de Citología Hematológica (GECH), Working Group into the Asociación Española de Hematología y Hemoterapia (AEHH)
- Published
- 2008
- Full Text
- View/download PDF
5. DNA profiling analysis of 100 consecutive de novo acute myeloid leukemia cases reveals patterns of genomic instability that affect all cytogenetic risk groups
- Author
-
Suela, J, Álvarez, S, Cifuentes, F, Largo, C, Ferreira, B I, Blesa, D, Ardanaz, M, García, R, Marquez, J A, Odero, M D, Calasanz, M J, and Cigudosa, J C
- Published
- 2007
- Full Text
- View/download PDF
6. Cryptic ins(2;11) with clonal evolution showing amplification of 11q23–q25 either on hsr(11) or on dmin, in a patient with AML-M2
- Author
-
Vazquez, I, Lahortiga, I, Agirre, X, Larrayoz, M J, Vizmanos, J L, Ardanaz, M T, Zeleznik-Le, N J, Calasanz, M J, and Odero, M D
- Published
- 2004
- Full Text
- View/download PDF
7. Myeloid sarcoma preceding an acute promyelocytic leukaemia with neuromeningeal infiltration
- Author
-
Piñán, M. A., Ardanaz, M. T., Guinea, J. M., and García-Ruiz, J. C.
- Published
- 2014
- Full Text
- View/download PDF
8. Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes
- Author
-
Calvo X, Arenillas L, Luno E, Senent L, Arnan M, Ramos F, Ardanaz M, Pedro C, Tormo M, Montoro J, Diez-Campelo M, Arrizabalagall B, Xicoy B, Bonanad S, Jerez A, Nomdedeu B, Ferrer A, Sanz G, Florensa L, and Grp Espanol Sindromes Mielodisplas
- Subjects
hemic and lymphatic diseases - Abstract
Erythroleukemia was considered an acute myeloid leukemia in the 2008 World Health Organization (WHO) classification and is defined by the presence of >= 50% bone marrow erythroblasts, having = 20% bone marrow myeloblasts from nonerythroid cells. Erythroleukemia shares clinicopathologic features with myelodysplastic syndromes, especially with erythroid-predominant myelodysplastic syndromes (>= 50% bone marrow erythroblasts). The upcoming WHO revision proposes to eliminate the nonerythroid blast cell count rule and to move erythroleukemia patients into the appropriate myelodysplastic syndrome category on the basis of the absolute blast cell count. We conducted a retrospective study of patients with de novo erythroleukemia and compared their clinico-biological features and outcome with those of de novo myelodysplastic syndromes, focusing on erythroid-predominant myelodysplastic syndromes. Median overall survival of 405 erythroid-predominant myelodysplastic syndromes without excess blasts was significantly longer than that observed in 57 erythroid-predominant refractory anemias with excess blasts-1 and in 59 erythroleukemias, but no significant difference was observed between erythroid-predominant refractory anemias with excess blasts-1 and erythroleukemias. In this subset of patients with >= 50% bone marrow erythroblasts and excess blasts, the presence of a high-risk karyotype defined by the International Prognostic Scoring System or by the Revised International Prognostic Scoring System was the main prognostic factor. In the same way, the survival of 459 refractory anemias with excess blasts-2, independently of having >= 20% bone marrow blasts from nonerythroid cells or not, was almost identical to the observed in 59 erythroleukemias. Interestingly, 11 low-blast count erythroleukemias with 5 to < 10% bone marrow blasts from total nucleated cells showed similar survival than the rest of erythroleukemias. Our data suggest that de novo erythroleukemia is in the spectrum of myelodysplastic syndromes with excess blasts and support its inclusion into future classifications of myelodysplastic syndromes.
- Published
- 2016
9. Cytogenetic Analysis of 280 Patients With Multiple Myeloma and Related Disorders: Primary Breakpoints and Clinical Correlations
- Author
-
Calasanz, M. J., primary, Cigudosa, J. C., additional, Odero, M. D., additional, Ferreira, C., additional, Ardanaz, M. T., additional, Fraile, A., additional, Carrasco, J. L., additional, Solé, F., additional, Cuesta, B., additional, and Gullón, A., additional
- Published
- 2017
- Full Text
- View/download PDF
10. What is the Outcome of Patients in the Intermediate IPSS-R Score Group? Spanish Approach for Better Stratification with Classical Tools
- Author
-
Guijo, A.M. Redondo, primary, Sánchez-Barba, M., additional, Santillana, G. Sanz, additional, Bernal, T., additional, Sangerman, M. Arnan, additional, Ortega, F. Ramos, additional, Olivé, C. Pedro, additional, Lozano, M.L. Amigo, additional, Betes, V. Marco, additional, Valcárcel, D., additional, Ardanaz, M., additional, Brunet, S., additional, Lleonart, J. Bargay, additional, Tormo, M., additional, Xicoy, B., additional, Nomdedeu, M., additional, Cadenas, F. López, additional, Berrocal, J.C. Caballero, additional, Cañizo, M.C.D., additional, and Díez-Campelo, M., additional
- Published
- 2017
- Full Text
- View/download PDF
11. Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes
- Author
-
Nomdedeu, M., Calvo, X., Pereira, A., Carrio, A., Gomez, C., Arias, A., Munoz, C., Sole, F., Luno, E., Cervera, J., Vallesp, T., Such, E., Sanz, G., Grau, J., Insunza, A., MJ Calasanz, Ardanaz, M. T., Hernandez, J. M., Azaceta, G., Alvarez, S., Sanchez, J., Martin, M. L., Bargay, J., Gomez, V., Cervero, C. J., Allegue, M. J., Collado, R., Campo, E., Esteve, J., Nomdedeu, B., and Costa, D.
- Subjects
Male ,Leukemia, Myelomonocytic, Chronic ,Middle Aged ,urologic and male genital diseases ,Prognosis ,Translocation, Genetic ,Survival Rate ,Spain ,hemic and lymphatic diseases ,Karyotyping ,Myelodysplastic Syndromes ,Humans ,Female ,Aged - Abstract
Chromosomal translocations are rare in the myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). With the exception of t(3q), translocations are not explicitly considered in the cytogenetic classification of the IPSS-R and their impact on disease progression and patient survival is unknown. The present study was aimed at determining the prognostic impact of translocations in the context of the cytogenetic classification of the IPSS-R. We evaluated 1,653 patients from the Spanish Registry of MDS diagnosed with MDS or CMML and an abnormal karyotype by conventional cytogenetic analysis. Translocations were identified in 168 patients (T group). Compared with the 1,485 patients with abnormal karyotype without translocations (non-T group), the T group had a larger proportion of patients with refractory anemia with excess of blasts and higher scores in both the cytogenetic and global IPSS-R. Translocations were associated with a significantly shorter survival and higher incidence of transformation into AML at univariate analysis but both features disapeared after multivariate adjustment for the IPSS-R cytogenetic category. Patients with single or double translocations other than t(3q) had an outcome similar to those in the non-T group in the intermediate cytogenetic risk category of the IPSS-R. In conclusion, the presence of translocations identifies a subgroup of MDS/CMML patients with a more aggressive clinical presentation that can be explained by a higher incidence of complex karyotypes. Single or double translocations other than t(3q) should be explicitly considered into the intermediate risk category of cytogenetic IPSS-R classification. (c) 2015 Wiley Periodicals, Inc.
- Published
- 2015
12. Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome
- Author
-
Valcárcel D, Ademà V, Solé F, Ortega M, Nomdedeu B, Sanz G, Luño E, Cañizo C, de la Serna J, Ardanaz M, Marco V, Collado R, Grau J, Montoro J, Mallo M, and Vallespí T
- Subjects
hemic and lymphatic diseases - Abstract
Complex karyotype (CK) is the poorest risk factor in patients with myelodysplastic syndrome (MDS). It has recently been reported that monosomal karyotype (MK) worsens the prognosis of patients with CK. PATIENTS AND METHODS; We analyzed 1,054 adult patients with MDS with an abnormal karyotype from the Spanish Registry of MDS. The aim of the study was to describe the incidence, characteristics, and prognosis of MK; the main end points were overall survival (OS) and leukemia-free survival.
- Published
- 2013
13. BIALLELIC LOSSES OF 13Q DO NOT CONFER A POORER OUTCOME IN CHRONIC LYMPHOCYTIC LEUKEMIA: ANALYSIS OF 627 PATIENTS WITH ISOLATED 13Q DELETION
- Author
-
Puiggros A, Delgado J, Rodriguez-Vicente A, Collado R, Aventin A, Luno E, Grau J, Marugan I, Ardanaz M, Gonzalez T, Valiente A, Osma M, Calasanz M, Salido M, Ivars D, Sanzo C, Ruiz-Xiville N, Carrio A, Gonzalez M, Benet I, Ortega M, Santacruz R, Fernandez E, Ortuno F, Abrisqueta P, Olavarria E, Oliveira A, Marco M, Arranz E, Cervera J, Batlle A, Abella E, Gimeno E, Ferra C, Terol M, Munoz C, Ferrer A, Loscertales J, Bosch F, Carbonell F, Sole F, Hernandez J, and Espinet B
- Published
- 2013
14. Prognostic impact on survival of an unsuccessful conventional cytogenetic study in patients with myelodysplastic syndromes (MDS)
- Author
-
Cervera, J., Sole, F., Haase, D., Luno, E., Such, E., Nomdedeu, B., Costa, D., Bernal, T., Vallespi, T., Bueno, J., Pedro, C., Mallo, M., Ardanaz, M. T., Calasanz, M. J., del Canizo, C., Hernandez-Rivas, J. M., Schanz, J., Steidl, C., Hildebrandt, B., Carbonell, F., Orero, M., Ramos, F., Marco, V., Tormo, M., Gomez, V., Andreu, R., Xicoy, B., Amigo, M. L., Munoz, J. A., Bonanad, S., Arrizabalaga, B., Senent, M. L., Germing, U., and Sanz, G. F.
- Published
- 2009
15. Compliance with good practice in early breast cancer treatment in relation to total national health expenditure
- Author
-
Danzon , Arlette, C Sant M Lucca F Berrino T Aareleid E Ardanaz M Bielska-Lasota M Cirilli C Colonna M Contiero P Garau I Grosclaude P Hakulinen T Hédelin G Izarzugaza I Lotti B Martinez-Garcia C Paci E Peignaux K Plesko I Rachtan J Sigona A Storm H Torella-Ramos A Traina , Allemani, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ) -Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)
- Subjects
[SDV.CAN]Life Sciences [q-bio]/Cancer ,[ SDV.CAN ] Life Sciences [q-bio]/Cancer - Published
- 2007
16. 261 - What is the Outcome of Patients in the Intermediate IPSS-R Score Group? Spanish Approach for Better Stratification with Classical Tools
- Author
-
Guijo, A.M. Redondo, Sánchez-Barba, M., Santillana, G. Sanz, Bernal, T., Sangerman, M. Arnan, Ortega, F. Ramos, Olivé, C. Pedro, Lozano, M.L. Amigo, Betes, V. Marco, Valcárcel, D., Ardanaz, M., Brunet, S., Lleonart, J. Bargay, Tormo, M., Xicoy, B., Nomdedeu, M., Cadenas, F. López, Berrocal, J.C. Caballero, Cañizo, M.C.D., and Díez-Campelo, M.
- Published
- 2017
- Full Text
- View/download PDF
17. Efecto de la aplicación de tratamientos combinados de aditivos sobre la inhibición del pardeamiento enzimático en manzanas cv. Granny Smith mínimamente procesadas
- Author
-
Denoya, G. I., Ardanaz, M., Sancho, A. M., Benítez, C. E., González, C., Guidi, S., Denoya, G. I., Ardanaz, M., Sancho, A. M., Benítez, C. E., González, C., and Guidi, S.
- Abstract
El pardeamiento enzimático, catalizado principalmente por la Enzima Polifenol Oxidasa (PPO), es uno de los principales problemas que afectan la calidad y limitan la vida útil de frutas y hortalizas mínimamente procesadas. Los compuestos tradicionalmente utilizados para inhibir la PPO, son los sulfitos. Sin embargo, se ha desalentado su utilización en la industria alimentaria debido a que se han registrado casos de reacciones alérgicas, especialmente en individuos asmáticos. Como consecuencia, en la actualidad, se evalúa la utilización de otros compuestos como potenciales inhibidores de la enzima, para garantizar productos frescos y naturales. En el presente trabajo, se analizó la evolución de la actividad de la enzima PPO y las características cromáticas de la pulpa de rodajas de manzanas cv. Granny Smith, tratadas por inmersión en una solución de aditivos. Los tratamientos utilizados fueron: I. 2% ácido ascórbico + 1% ácido cítrico + 0,5% EDTA, II. 1% ácido ascórbico + 0,5 % ácido cítrico + 0,25% EDTA y III. agua, empleada como control. Durante el almacenamiento, se evaluaron las coordenadas de color del espacio CIE L*a*b* de las rodajas y se demostró que los tratamientos I y II fueron efectivos en evitar el pardeamiento de la fruta. La evaluación espectrofotométrica de la actividad enzimática de la PPO, en extractos de manzanas sometidas a los distintos tratamientos, mostró que el más severo (I) fue el que produjo el mayor grado de inhibición de la enzima, en todos los tiempos analizados. Se propone evaluar a futuro, la efectividad de estos inhibidores "in vitro" a efectos de compararlos con los resultados obtenidos en rodajas de manzana., Enzymatic browning, which is mainly catalyzed by the enzyme poliphenol oxidase (PPO), is one of the major problems affecting quality and limiting shelf life of fresh cut fruits and vegetables. Traditionally, sulfites are used to inhibit the enzyme. However, its presence in the food has induced allergenic reactions, particularly in asthmatic persons. Consequently, it has been evaluated the effect of other PPO inhibitors in order to obtain fresh and natural products. In the present work, the evolution of PPO activity and the chromatic characteristics of the pulp were evaluated in cv. Granny Smith apple slices. The slices were submitted to three treatments: I. 2% ascorbic acid + 1% citric acid + 0.5% EDTA; II. 1% ascorbic acid + 0.5% citric acid + 0.25% EDTA; and III. water, used as control. During the storage, parameters of the CIE L*a*b* color space of the slices were evaluated, indicating that both treatments containing additives were effective in preventing browning. The specific activity of PPO was determined spectrophotometrically in apple extracts obtained from each treatment. The results indicated that the stronger treatment (I) had induced the most effective inhibition of the enzyme. On view of the present results, It is proposed to evaluate the "in vitro" effectiveness of the inhibitors in order to compare these results with the ones obtained with apple slices.
- Published
- 2012
18. Myeloid sarcoma preceding an acute promyelocytic leukaemia with neuromeningeal infiltration
- Author
-
Piñán, M. A., primary, Ardanaz, M. T., additional, Guinea, J. M., additional, and García-Ruiz, J. C., additional
- Published
- 2013
- Full Text
- View/download PDF
19. Identification of Poor Risk Patients in Low and Intermediate-1 (Int-1) IPSS MDS with the New Ipssr Index and Comparison with Other Prognostic Indexes. A Study by the Spanish Group of MDS (GESMD)
- Author
-
Valcárcel, David, primary, Sanz, Guillermo, additional, Ortega, Margarita, additional, Nomdedeu, Benet, additional, Luño, Elisa, additional, Diez-Campelo, María, additional, Ardanaz, M. Teresa, additional, Pedro, Carmen, additional, Montoro, Julia, additional, Collado, Rosa, additional, Andreu, Rafa, additional, Marco, Victor, additional, Cedena, Maria Teresa, additional, de Paz, Raquel, additional, Tormo, Mar, additional, Xicoy, Blanca, additional, Ramos, Fernando, additional, Bargay, Joan, additional, Gonzalez, Bernardo, additional, Brunet, Salut, additional, Muñoz, Juan Antonio, additional, Gomez, Valle, additional, Bailen, Alicia, additional, Sanchez, Joaquin, additional, and Vallespi, Teresa, additional
- Published
- 2012
- Full Text
- View/download PDF
20. 297 Prognostic impact of severe thrombocytopenia in low risk myelodysplastic syndrome
- Author
-
Gonzalez-Porras, J.R., primary, Cordoba, I., additional, Such, E., additional, Nomdedeu, B., additional, Vallespi, T., additional, Carbonell, F., additional, Luño, E., additional, Ardanaz, M., additional, Ramos, F., additional, Pedro, C., additional, Gomez, V., additional, de Paz, R., additional, Andreu, R., additional, Marco, V., additional, Tormo, M., additional, Bonanad, S., additional, de la Serna, J., additional, Muñoz, J.A., additional, Benlloch, L., additional, Costa, D., additional, Bueno, J., additional, Bernal, T., additional, Sanz, G., additional, and del Cañizo, C., additional
- Published
- 2011
- Full Text
- View/download PDF
21. Cytogenetic risk stratification in chronic myelomonocytic leukemia
- Author
-
Such, E., primary, Cervera, J., additional, Costa, D., additional, Sole, F., additional, Vallespi, T., additional, Luno, E., additional, Collado, R., additional, Calasanz, M. J., additional, Hernandez-Rivas, J. M., additional, Cigudosa, J. C., additional, Nomdedeu, B., additional, Mallo, M., additional, Carbonell, F., additional, Bueno, J., additional, Ardanaz, M. T., additional, Ramos, F., additional, Tormo, M., additional, Sancho-Tello, R., additional, Canizo, C. d., additional, Gomez, V., additional, Marco, V., additional, Xicoy, B., additional, Bonanad, S., additional, Pedro, C., additional, Bernal, T., additional, and Sanz, G. F., additional
- Published
- 2010
- Full Text
- View/download PDF
22. 6006 ORAL DNA repair gene ATM polymorphisms and risk of chronic lymphocytic leukaemia
- Author
-
Martín Guerrero, I., primary, Colomer, D., additional, Enjuanes, A., additional, Bosch, F., additional, Villamar, N., additional, Ardanaz, M., additional, Marco, F., additional, Campo, E., additional, and García-Orad, A., additional
- Published
- 2007
- Full Text
- View/download PDF
23. Culicoides midges in Catalonia (Spain), with special reference to likely bluetongue virus vectors
- Author
-
Monteys, V. Sarto I, primary and Saiz-Ardanaz, M., additional
- Published
- 2003
- Full Text
- View/download PDF
24. Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: Primary breakpoints and clinical correlations
- Author
-
Calasanz, María J., primary, Cigudosa, Juan C., additional, Odero, María D., additional, Ferreira, Carmen, additional, Ardanaz, M. Teresa, additional, Fraile, Aurora, additional, Carrasco, José L., additional, Solé, Françesc, additional, Cuesta, Braulia, additional, and Gullón, Arturo, additional
- Published
- 1997
- Full Text
- View/download PDF
25. Comparative genomic hybridization and amplotyping by arbitrarily primed PCR in stage A B-CLL
- Author
-
Odero, M. D., Soto, J. L., Matutes, E., Martin-Subero, J. I., Zudaire, I., Rao, P. H., Cigudosa, J. C., Ardanaz, M. T., Chaganti, R. S., and Perucho, M.
- Published
- 2001
- Full Text
- View/download PDF
26. Prognostic relevance of specific chromosomal abnormalities in chronic myelomonocytic leukemia
- Author
-
Such, E., Cervera, J., Costa, D., Sole, F., Luno, E., Nomdedeu, B., Vallespi, T., Carbonell, F., Ardanaz, M. T., Ramos, F., Tormo, M., Del Canizo, C., Mallo, M., Blanca Xicoy, Gomez, V., Marco, V., Bonanad, S., Collado, R., Calasanz, M. J., Cruz-Cigudosa, J., Hernandez-Rivas, J. M., Senent, M. L., Pedro, C., Bernal, T., Bueno, J., and Sanz, G. F.
27. Complex Karyotype Including Trisomy 8 in a Case of B-Chronic Lymphocytic Leukemia
- Author
-
Cigudosa, J. C., Calasanz, M. J., Gullon, A., and Ardanaz, M. T.
- Published
- 1992
- Full Text
- View/download PDF
28. Global surveillance of trends in cancer survival 2000-14 (concord-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries
- Author
-
Claudia Allemani, Tomohiro Matsuda, Veronica Di Carlo, Rhea Harewood, Melissa Matz, Maja Nikšić, Audrey Bonaventure, Mikhail Valkov, Christopher J Johnson, Jacques Estève, Olufemi J Ogunbiyi, Gulnar Azevedo e Silva, Wan-Qing Chen, Sultan Eser, Gerda Engholm, Charles A Stiller, Alain Monnereau, Ryan R Woods, Otto Visser, Gek Hsiang Lim, Joanne Aitken, Hannah K Weir, Michel P Coleman, S Bouzbid, M Hamdi-Chérif, Z Zaidi, K Meguenni, D Regagba, S Bayo, T Cheick Bougadari, S S Manraj, A Fabowale, O J Ogunbiyi, D Bradshaw, N I M Somdyala, I Kumcher, F Moreno, G H Calabrano, S B Espinola, B Carballo Quintero, R Fita, M C Diumenjo, W D Laspada, S G Ibañez, C A Lima, P C F De Souza, K Del Pino, C Laporte, M P Curado, J C de Oliveira, C L A Veneziano, D B Veneziano, M R D O Latorre, L F Tanaka, M S Rebelo, M O Santos, G Azevedo e Silva, J C Galaz, M Aparicio Aravena, J Sanhueza Monsalve, D A Herrmann, S Vargas, V M Herrera, C J Uribe, L E Bravo, L S Garcia, N E Arias-Ortiz, D Morantes, D M Jurado, M C Yépez Chamorro, S Delgado, M Ramirez, Y H Galán Alvarez, P Torres, F Martínez-Reyes, L Jaramillo, R Quinto, J, M Mendoza, P Cueva, J G Yépez, B Bhakkan, J Deloumeaux, C Joachim, J Macni, R Carrillo, J Shalkow Klincovstein, R Rivera Gomez, E Poquioma, G Tortolero-Luna, D Zavala, R Alonso, E Barrios, A Eckstrand, C Nikiforuk, R R Woods, G Noonan, D Turner, E Kumar, B Zhang, F R McCrate, S Ryan, M MacIntyre, N Saint-Jacques, D E Nishri, C A McClure, K A Vriends, S Kozie, H Stuart-Panko, T Freeman, J T George, J T Brockhouse, D K O'Brien, A Holt, L Almon, S Kwong, C Morris, R Rycroft, L Mueller, C E Phillips, H Brown, B Cromartie, A G Schwartz, F Vigneau, G M Levin, B Wohler, R Bayakly, K C Ward, S L Gomez, M McKinley, R Cress, M D Green, K Miyagi, C J Johnson, L P Ruppert, C F Lynch, B Huang, T C Tucker, D Deapen, L Liu, M C Hsieh, X C Wu, M Schwenn, S T Gershman, R C Knowlton, G Alverson, G E Copeland, S Bushhouse, D B Rogers, J Jackson-Thompson, D Lemons, H J Zimmerman, M Hood, J Roberts-Johnson, J R Rees, B Riddle, K S Pawlish, A Stroup, C Key, C Wiggins, A R Kahn, M J Schymura, S Radhakrishnan, C Rao, L K Giljahn, R M Slocumb, R E Espinoza, F Khan, K G Aird, T Beran, J J Rubertone, S J Slack, L Garcia, D L Rousseau, T A Janes, S M Schwartz, S W Bolick, D M Hurley, M A Whiteside, P Miller-Gianturco, M A Williams, K Herget, C Sweeney, A T Johnson, M B Keitheri Cheteri, P Migliore Santiago, S E Blankenship, S Farley, R Borchers, R Malicki, J R Espinoza, J Grandpre, H K Weir, R Wilson, B K Edwards, A Mariotto. Y Lei, N Wang, J S Chen, Y Zhou, Y T He, G H Song, X P Gu, D Mei, H J Mu, H M Ge, T H Wu, Y Y Li, D L Zhao, F Jin, J H Zhang, F D Zhu, Q Junhua, Y L Yang, C X Jiang, W Biao, J Wang, Q L Li, H Yi, X Zhou, J Dong, W Li, F X Fu, S Z Liu, J G Chen, J Zhu, Y H Li, Y Q Lu, M Fan, S Q Huang, G P Guo, H Zhaolai, K Wei, W Q Chen, H Zeng, A V Demetriou, W K Mang, K C Ngan, A C Kataki, M Krishnatreya, P A Jayalekshmi, P Sebastian, A Nandakumar, R Malekzadeh, G Roshandel, L Keinan-Boker, B G Silverman, H Ito, H Nakagawa, M Sato, F Tobori, I Nakata, N Teramoto, M Hattori, Y Kaizaki, F Moki, H Sugiyama, M Utada, M Nishimura, K Yoshida, K Kurosawa, Y Nemoto, H Narimatsu, M Sakaguchi, S Kanemura, M Naito, R Narisawa, I Miyashiro, K Nakata, S Sato, M Yoshii, I Oki, N Fukushima, A Shibata, K Iwasa, C Ono, T Matsuda, O Nimri, K W Jung, Y J Won, E Alawadhi, A Elbasmi, A Ab Manan, F Adam, E Sanjaajmats, U Tudev, C Ochir, A M Al Khater, M M El Mistiri, G H Lim, Y Y Teo, C J Chiang, W C Lee, R Buasom, S Sangrajrang, S Kamsaard, S Wiangnon, K Daoprasert, D Pongnikorn, A Leklob, S Sangkitipaiboon, S L Geater, H Sriplung, O Ceylan, I Kög, O Dirican, T Köse, T Gurbuz, F E Karaşahin, D Turhan, U Aktaş, Y Halat, S Eser, C I Yakut, M Altinisik, Y Cavusoglu, A Türkköylü, N Üçüncü, M Hackl, A A Zborovskaya, O V Aleinikova, K Henau, L Van Eycken, Z Valerianova, M R Yordanova, M Šekerija, L Dušek, M Zvolský, G Engholm, H Storm, K Innos, M Mägi, N Malila, K Seppä, J Jégu, M Velten, E Cornet, X Troussard, A M Bouvier, A V Guizard, V Bouvier, G Launoy, P Arveux, M Maynadié, M Mounier, A S Worono, M Daoulas, M Robaszkiewicz, J Clavel, S Goujon, B Lacour, I Baldi, C Pouchieu, B Amadeo, G Coureau, A Monnereau, S Orazio, P M Preux, F Rharbaoui, E Marrer, B Trétarre, M Colonna, P Delafosse, K Ligier, S Plouvier, A Cowppli-Bony, F Molinié, S Bara, O Ganry, B Lapôtre- Ledoux, P Grosclaude, N Bossard, Z Uhry, F Bray, M Piñeros, J Estève, R Stabenow, H Wilsdorf-Köhler, A Eberle, S Luttmann, I Löhden, A L Nennecke, J Kieschke, E Sirri, K Emrich, S R Zeissig, B Holleczek, N Eisemann, A Katalinic, R A Asquez, V Kumar, E Petridou, E J Ólafsdóttir, L Tryggvadóttir, K Clough-Gorr, P M Walsh, H Sundseth, G Mazzoleni, F Vittadello, E Coviello, F Cuccaro, R Galasso, G Sampietro, A Giacomin, M Magoni, A Ardizzone, A D'Argenzio, M Castaing, G Grosso, A M Lavecchia, A Sutera Sardo, G Gola, L Gatti, P Ricci, S Ferretti, D Serraino, A Zucchetto, M V Celesia, R A Filiberti, F Pannozzo, A Melcarne, F Quarta, A G Russo, G Carrozzi, C Cirilli, L Cavalieri d'Oro, M Rognoni, M Fusco, M F Vitale, M Usala, R Cusimano, W Mazzucco, M Michiara, P Sgargi, L Boschetti, E Borciani, P Seghini, M M Maule, F Merletti, R Tumino, P Mancuso, M Vicentini, T Cassetti, R Sassatelli, F Falcini, S Giorgetti, A L Caiazzo, R Cavallo, R Cesaraccio, D R Pirino, M L Contrino, F Tisano, A C Fanetti, S Maspero, S Carone, A Mincuzzi, G Candela, T Scuderi, M A Gentilini, S Pier, S Rosso, A Barchielli, A Caldarella, F Bianconi, F Stracci, P Contiero, G Tagliabue, M Rugge, M Zorzi, S Beggiato, A Brustolin, F Berrino, G Gatta, M Sant, C Buzzoni, L Mangone, R Capocaccia, R De Angelis, R Zanetti, A Maurina, S Pildava, N Lipunova, I Vincerževskienė, D Agius, N Calleja, S Siesling, O Visser, Larønningen, B Møller, A Dyzmann-Sroka, M Trojanowski, S Góźdź, R Mężyk, T Mierzwa, L Molong, J Rachtan, S Szewczyk, J Błaszczyk, K Kępska, B Kościańska, K Tarocińska, M Zwierko, K Drosik, K M Maksimowicz, E Purwin-Porowska, E Reca, J Wójcik-Tomaszewska, A Tukiendorf, M Grądalska-Lampart, A U Radziszewska, A Gos, M Talerczyk, M Wyborska, J A Didkowska, U Wojciechowska, M Bielska-Lasota, G Forjaz de Lacerda, R A Rego, J Bastos, M A Silva, L Antunes, J Laranja Pontes, A Mayer-da-Silva, A Miranda, L M Blaga, D Coza, Russia: M Y Valkov, L Gusenkova, O Lazarevich, O Prudnikova, D M Vjushkov, A G Egorova, A E Orlov, L A Kudyakov, L V Pikalova, J Adamcik, C Safaei Diba, M Primic-Žakelj, V Zadnik, N Larrañaga, A Lopez de Munain, A A Herrera, R Redondas, R Marcos-Gragera, M L Vilardell Gil, E Molina, M J Sánchez Perez, P Franch Sureda, M Ramos Montserrat, M D Chirlaque, C Navarro, E E Ardanaz, M M Guevara, R Fernández-Delgado, R Peris-Bonet, M Carulla, J Galceran, C Alberich, M Vicente-Raneda, S Khan, D Pettersson, P Dickman, I Avelina, K Staehelin, B Camey, C Bouchardy, R Schaar, H Frick, C Herrmann, J L Bulliard, M Maspoli-Conconi, C E Kuehni, S M Redmond, A Bordoni, L Ortelli, A Chiolero, I Konzelmann, K L Matthes, S Rohrmann, Broggio, J Rashbass, D Fitzpatrick, A Gavin, D I Clark, A J Deas, D W Huws, C White, C Allemani, A Bonaventure, M P Coleman, V Di Carlo, R Harewood, M Matz, L Montel, M Nikšić, B Rachet, A D Turculeț, R Stephens, C A Stiller, E Chalker, H Phung, R Walton, H You, S Guthridge, F Johnson, J Aitken, P Gordon, K D'Onise, K Priest, B C Stokes, A Venn, H Farrugia, V Thurs eld, J Dowlin, D Currow, J Hendrix, C Lewis, Tıp Fakültesi, Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Claudia Allemani, Tomohiro Matsuda, Veronica Di Carlo, Rhea Harewood, Melissa Matz, Maja Nikšić, Audrey Bonaventure, Mikhail Valkov, Christopher J Johnson, Jacques Estève, Olufemi J Ogunbiyi, Gulnar Azevedo e Silva, Wan-Qing Chen, Sultan Eser, Gerda Engholm, Charles A Stiller, Alain Monnereau, Ryan R Woods, Otto Visser, Gek Hsiang Lim, Joanne Aitken, Hannah K Weir, Michel P Coleman, S Bouzbid, M Hamdi-Chérif, Z Zaidi, K Meguenni, D Regagba, S Bayo, T Cheick Bougadari, S S Manraj, A Fabowale, O J Ogunbiyi, D Bradshaw, N I M Somdyala, I Kumcher, F Moreno, G H Calabrano, S B Espinola, B Carballo Quintero, R Fita, M C Diumenjo, W D Laspada, S G Ibañez, C A Lima, P C F De Souza, K Del Pino, C Laporte, M P Curado, J C de Oliveira, C L A Veneziano, D B Veneziano, M R D O Latorre, L F Tanaka, M S Rebelo, M O Santos, G Azevedo e Silva, J C Galaz, M Aparicio Aravena, J Sanhueza Monsalve, D A Herrmann, S Vargas, V M Herrera, C J Uribe, L E Bravo, L S Garcia, N E Arias-Ortiz, D Morantes, D M Jurado, M C Yépez Chamorro, S Delgado, M Ramirez, Y H Galán Alvarez, P Torres, F Martínez-Reyes, L Jaramillo, R Quinto, J, M Mendoza, P Cueva, J G Yépez, B Bhakkan, J Deloumeaux, C Joachim, J Macni, R Carrillo, J Shalkow Klincovstein, R Rivera Gomez, E Poquioma, G Tortolero-Luna, D Zavala, R Alonso, E Barrios, A Eckstrand, C Nikiforuk, R R Woods, G Noonan, D Turner, E Kumar, B Zhang, F R McCrate, S Ryan, M MacIntyre, N Saint-Jacques, D E Nishri, C A McClure, K A Vriends, S Kozie, H Stuart-Panko, T Freeman, J T George, J T Brockhouse, D K O'Brien, A Holt, L Almon, S Kwong, C Morris, R Rycroft, L Mueller, C E Phillips, H Brown, B Cromartie, A G Schwartz, F Vigneau, G M Levin, B Wohler, R Bayakly, K C Ward, S L Gomez, M McKinley, R Cress, M D Green, K Miyagi, C J Johnson, L P Ruppert, C F Lynch, B Huang, T C Tucker, D Deapen, L Liu, M C Hsieh, X C Wu, M Schwenn, S T Gershman, R C Knowlton, G Alverson, G E Copeland, S Bushhouse, D B Rogers, J Jackson-Thompson, D Lemons, H J Zimmerman, M Hood, J Roberts-Johnson, J R Rees, B Riddle, K S Pawlish, A Stroup, C Key, C Wiggins, A R Kahn, M J Schymura, S Radhakrishnan, C Rao, L K Giljahn, R M Slocumb, R E Espinoza, F Khan, K G Aird, T Beran, J J Rubertone, S J Slack, L Garcia, D L Rousseau, T A Janes, S M Schwartz, S W Bolick, D M Hurley, M A Whiteside, P Miller-Gianturco, M A Williams, K Herget, C Sweeney, A T Johnson, M B Keitheri Cheteri, P Migliore Santiago, S E Blankenship, S Farley, R Borchers, R Malicki, J R Espinoza, J Grandpre, H K Weir, R Wilson, B K Edwards, A Mariotto. Y Lei, N Wang, J S Chen, Y Zhou, Y T He, G H Song, X P Gu, D Mei, H J Mu, H M Ge, T H Wu, Y Y Li, D L Zhao, F Jin, J H Zhang, F D Zhu, Q Junhua, Y L Yang, C X Jiang, W Biao, J Wang, Q L Li, H Yi, X Zhou, J Dong, W Li, F X Fu, S Z Liu, J G Chen, J Zhu, Y H Li, Y Q Lu, M Fan, S Q Huang, G P Guo, H Zhaolai, K Wei, W Q Chen, H Zeng, A V Demetriou, W K Mang, K C Ngan, A C Kataki, M Krishnatreya, P A Jayalekshmi, P Sebastian, A Nandakumar, R Malekzadeh, G Roshandel, L Keinan-Boker, B G Silverman, H Ito, H Nakagawa, M Sato, F Tobori, I Nakata, N Teramoto, M Hattori, Y Kaizaki, F Moki, H Sugiyama, M Utada, M Nishimura, K Yoshida, K Kurosawa, Y Nemoto, H Narimatsu, M Sakaguchi, S Kanemura, M Naito, R Narisawa, I Miyashiro, K Nakata, S Sato, M Yoshii, I Oki, N Fukushima, A Shibata, K Iwasa, C Ono, T Matsuda, O Nimri, K W Jung, Y J Won, E Alawadhi, A Elbasmi, A Ab Manan, F Adam, E Sanjaajmats, U Tudev, C Ochir, A M Al Khater, M M El Mistiri, G H Lim, Y Y Teo, C J Chiang, W C Lee, R Buasom, S Sangrajrang, S Kamsaard, S Wiangnon, K Daoprasert, D Pongnikorn, A Leklob, S Sangkitipaiboon, S L Geater, H Sriplung, O Ceylan, I Kög, O Dirican, T Köse, T Gurbuz, F E Karaşahin, D Turhan, U Aktaş, Y Halat, S Eser, C I Yakut, M Altinisik, Y Cavusoglu, A Türkköylü, N Üçüncü, M Hackl, A A Zborovskaya, O V Aleinikova, K Henau, L Van Eycken, Z Valerianova, M R Yordanova, M Šekerija, L Dušek, M Zvolský, G Engholm, H Storm, K Innos, M Mägi, N Malila, K Seppä, J Jégu, M Velten, E Cornet, X Troussard, A M Bouvier, A V Guizard, V Bouvier, G Launoy, P Arveux, M Maynadié, M Mounier, A S Worono, M Daoulas, M Robaszkiewicz, J Clavel, S Goujon, B Lacour, I Baldi, C Pouchieu, B Amadeo, G Coureau, A Monnereau, S Orazio, P M Preux, F Rharbaoui, E Marrer, B Trétarre, M Colonna, P Delafosse, K Ligier, S Plouvier, A Cowppli-Bony, F Molinié, S Bara, O Ganry, B Lapôtre- Ledoux, P Grosclaude, N Bossard, Z Uhry, F Bray, M Piñeros, J Estève, R Stabenow, H Wilsdorf-Köhler, A Eberle, S Luttmann, I Löhden, A L Nennecke, J Kieschke, E Sirri, K Emrich, S R Zeissig, B Holleczek, N Eisemann, A Katalinic, R A Asquez, V Kumar, E Petridou, E J Ólafsdóttir, L Tryggvadóttir, K Clough-Gorr, P M Walsh, H Sundseth, G Mazzoleni, F Vittadello, E Coviello, F Cuccaro, R Galasso, G Sampietro, A Giacomin, M Magoni, A Ardizzone, A D'Argenzio, M Castaing, G Grosso, A M Lavecchia, A Sutera Sardo, G Gola, L Gatti, P Ricci, S Ferretti, D Serraino, A Zucchetto, M V Celesia, R A Filiberti, F Pannozzo, A Melcarne, F Quarta, A G Russo, G Carrozzi, C Cirilli, L Cavalieri d'Oro, M Rognoni, M Fusco, M F Vitale, M Usala, R Cusimano, W Mazzucco, M Michiara, P Sgargi, L Boschetti, E Borciani, P Seghini, M M Maule, F Merletti, R Tumino, P Mancuso, M Vicentini, T Cassetti, R Sassatelli, F Falcini, S Giorgetti, A L Caiazzo, R Cavallo, R Cesaraccio, D R Pirino, M L Contrino, F Tisano, A C Fanetti, S Maspero, S Carone, A Mincuzzi, G Candela, T Scuderi, M A Gentilini, S Pier, S Rosso, A Barchielli, A Caldarella, F Bianconi, F Stracci, P Contiero, G Tagliabue, M Rugge, M Zorzi, S Beggiato, A Brustolin, F Berrino, G Gatta, M Sant, C Buzzoni, L Mangone, R Capocaccia, R De Angelis, R Zanetti, A Maurina, S Pildava, N Lipunova, I Vincerževskienė, D Agius, N Calleja, S Siesling, O Visser, Larønningen, B Møller, A Dyzmann-Sroka, M Trojanowski, S Góźdź, R Mężyk, T Mierzwa, L Molong, J Rachtan, S Szewczyk, J Błaszczyk, K Kępska, B Kościańska, K Tarocińska, M Zwierko, K Drosik, K M Maksimowicz, E Purwin-Porowska, E Reca, J Wójcik-Tomaszewska, A Tukiendorf, M Grądalska-Lampart, A U Radziszewska, A Gos, M Talerczyk, M Wyborska, J A Didkowska, U Wojciechowska, M Bielska-Lasota, G Forjaz de Lacerda, R A Rego, J Bastos, M A Silva, L Antunes, J Laranja Pontes, A Mayer-da-Silva, A Miranda, L M Blaga, D Coza, Russia: M Y Valkov, L Gusenkova, O Lazarevich, O Prudnikova, D M Vjushkov, A G Egorova, A E Orlov, L A Kudyakov, L V Pikalova, J Adamcik, C Safaei Diba, M Primic-Žakelj, V Zadnik, N Larrañaga, A Lopez de Munain, A A Herrera, R Redondas, R Marcos-Gragera, M L Vilardell Gil, E Molina, M J Sánchez Perez, P Franch Sureda, M Ramos Montserrat, M D Chirlaque, C Navarro, E E Ardanaz, M M Guevara, R Fernández-Delgado, R Peris-Bonet, M Carulla, J Galceran, C Alberich, M Vicente-Raneda, S Khan, D Pettersson, P Dickman, I Avelina, K Staehelin, B Camey, C Bouchardy, R Schaar, H Frick, C Herrmann, J L Bulliard, M Maspoli-Conconi, C E Kuehni, S M Redmond, A Bordoni, L Ortelli, A Chiolero, I Konzelmann, K L Matthes, S Rohrmann, Broggio, J Rashbass, D Fitzpatrick, A Gavin, D I Clark, A J Deas, D W Huws, C White, C Allemani, A Bonaventure, M P Coleman, V Di Carlo, R Harewood, M Matz, L Montel, M Nikšić, B Rachet, A D Turculeț, R Stephens, C A Stiller, E Chalker, H Phung, R Walton, H You, S Guthridge, F Johnson, J Aitken, P Gordon, K D'Onise, K Priest, B C Stokes, A Venn, H Farrugia, V Thurs eld, J Dowlin, D Currow, J Hendrix, C Lewis
- Subjects
0301 basic medicine ,Universal Health Coverage ,population-based registries ,Relative Survival ,Settore MED/42 - Igiene Generale E Applicata ,Cancer -- Treatment ,Humans ,Neoplasms ,Population Surveillance ,Registries ,Survival Rate ,Medicine (all) ,0302 clinical medicine ,cancer survival ,education.field_of_study ,Relative survival ,EPICENE ,General Medicine ,3. Good health ,trend ,030220 oncology & carcinogenesis ,Public-Health ,cancer surveillance ,Liver cancer ,survival ,cancer registry ,CONCORD-3 ,Cure ,Childhood-Cancer ,medicine.medical_specialty ,population-based cancer registries ,Womens Cancers ,Population ,Medicine (all),cancer survival, population-based cancer registries ,Socio-culturale ,United-States ,Article ,03 medical and health sciences ,Breast cancer ,Cancer epidemiology ,medicine ,Nordic-Countries ,Cancer -- Mortality ,education ,Survival rate ,Cancer prevention ,Alternative Approach ,business.industry ,Public health ,Cancer ,Cancer -- Patients -- Long-term care ,medicine.disease ,030104 developmental biology ,High-Income Countries ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,business ,Demography - Abstract
Eser, Sultan (Balikesir Author), Background In 2015, the second cycle of the CONCORD programme established global surveillance of cancer survival as a metric of the effectiveness of health systems and to inform global policy on cancer control. CONCORD-3 updates the worldwide surveillance of cancer survival to 2014. Methods CONCORD-3 includes individual records for 37.5 million patients diagnosed with cancer during the 15-year period 2000-14. Data were provided by 322 population-based cancer registries in 71 countries and territories, 47 of which provided data with 100% population coverage. The study includes 18 cancers or groups of cancers: oesophagus, stomach, colon, rectum, liver, pancreas, lung, breast (women), cervix, ovary, prostate, and melanoma of the skin in adults, and brain tumours, leukaemias, and lymphomas in both adults and children. Standardised quality control procedures were applied; errors were rectified by the registry concerned. We estimated 5-year net survival. Estimates were age-standardised with the International Cancer Survival Standard weights.Findings For most cancers, 5-year net survival remains among the highest in the world in the USA and Canada, in Australia and New Zealand, and in Finland, Iceland, Norway, and Sweden. For many cancers, Denmark is closing the survival gap with the other Nordic countries. Survival trends are generally increasing, even for some of the more lethal cancers: in some countries, survival has increased by up to 5% for cancers of the liver, pancreas, and lung. For women diagnosed during 2010-14, 5-year survival for breast cancer is now 89.5% in Australia and 90.2% in the USA, but international differences remain very wide, with levels as low as 66.1% in India. For gastrointestinal cancers, the highest levels of 5-year survival are seen in southeast Asia: in South Korea for cancers of the stomach (68.9%), colon (71.8%), and rectum (71.1%); in Japan for oesophageal cancer (36.0%); and in Taiwan for liver cancer (27.9%). By contrast, in the same world region, survival is generally lower than elsewhere for melanoma of the skin (59.9% in South Korea, 52.1% in Taiwan, and 49.6% in China), and for both lymphoid malignancies (52.5%, 50.5%, and 38.3%) and myeloid malignancies (45.9%, 33.4%, and 24.8%). For children diagnosed during 2010-14, 5-year survival for acute lymphoblastic leukaemia ranged from 49.8% in Ecuador to 95.2% in Finland. 5-year survival from brain tumours in children is higher than for adults but the global range is very wide (from 28.9% in Brazil to nearly 80% in Sweden and Denmark). Interpretation The CONCORD programme enables timely comparisons of the overall effectiveness of health systems in providing care for 18 cancers that collectively represent 75% of all cancers diagnosed worldwide every year. It contributes to the evidence base for global policy on cancer control. Since 2017, the Organisation for Economic Co-operation and Development has used findings from the CONCORD programme as the official benchmark of cancer survival, among their indicators of the quality of health care in 48 countries worldwide. Governments must recognise population-based cancer registries as key policy tools that can be used to evaluate both the impact of cancer prevention strategies and the effectiveness of health systems for all patients diagnosed with cancer., American Cancer Society Centers for Disease Control and Prevention Swiss Re Swiss Cancer Research foundation Swiss Cancer League Institut National du Cancer La Ligue Contre le Cancer Rossy Family Foundation US National Cancer Institute Susan G Komen Foundation
- Published
- 2018
- Full Text
- View/download PDF
29. Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia.
- Author
-
Xicoy B, Germing U, Jimenez MJ, Garcia O, Garcia R, Schemenau J, Pedro C, Luño E, Bernal T, González B, Strupp C, Ardanaz M, Kuendgen A, Cedena MT, Neukirchen J, Calabuig M, Brunet S, Medina A, Amigo ML, Ramos F, Callejas M, Díez-Campelo M, Bailén A, Collado R, Vicente A, Arnan M, Valcarcel D, Arilla MJ, Zamora L, Benlloch L, and Sanz G
- Subjects
- Aged, Aged, 80 and over, Anemia diagnosis, Anemia mortality, Disease Progression, Female, Follow-Up Studies, Hematinics administration & dosage, Hematinics adverse effects, Humans, Leukemia, Myelomonocytic, Chronic diagnosis, Leukemia, Myelomonocytic, Chronic mortality, Male, Middle Aged, Survival Analysis, Treatment Outcome, Anemia drug therapy, Anemia etiology, Hematinics therapeutic use, Leukemia, Myelomonocytic, Chronic complications
- Abstract
Background: The efficacy of erythropoietic-stimulating agents (ESA) in chronic myelomonocytic leukemia (CMML) is unknown. Our objective was to analyze erythroid response (ER) and overall survival (OS) in a series of 94 patients with CMML treated with ESA., Methods: We analyzed a series of 94 patients with CMML treated with ESA included in the Spanish and Düsseldorf-MDS registries., Findings: ER was observed in 64% of patients and red blood cell (RBC) transfusion independence in 31%. The median duration of ER was 7 months (range, 0-88). CPSS and EPO level were significantly associated with ER in multivariate analysis (P = 0.003). Considering only patients with CPSS low- or intermediate-1-risk group, the absence of RBC transfusion dependence and erythropoietin (EPO) level predicted ER (P = 0.003 and P = 0.008, respectively). In multivariate analysis, only the EPO level retained its prognostic value (P = 0.029). Achievement of ER correlated with a better survival since ER evaluation (P = 0.016)., Interpretation: The CPSS and EPO levels are adequate tools to select CMML patients with symptomatic anemia who may benefit from treatment with ESA. A significant ER to ESA is expected in anemic patients with low/intermediate-1 CMML risk by the CPSS and a low endogenous serum EPO level., (© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2016
- Full Text
- View/download PDF
30. Methylation of CpG sites in BCL2 major breakpoint region and the increase of BCL2/JH translocation with aging.
- Author
-
Martin-Guerrero I, de Prado E, Ardanaz M, Martin-Arruti M, Garcia-Orad C, Guerra I, Ruiz I, Zabalza I, and Garcia-Orad A
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Aging metabolism, Child, Child, Preschool, DNA Methylation, Female, Gene Frequency, Humans, Infant, Male, Middle Aged, Polymerase Chain Reaction, Proto-Oncogene Proteins c-bcl-2 metabolism, Reference Values, Retrospective Studies, Translocation, Genetic, Young Adult, Aging genetics, CpG Islands genetics, Polymorphism, Genetic, Proto-Oncogene Proteins c-bcl-2 genetics
- Abstract
The BCL2 breakage mechanism has been shown to be highly dependent on DNA methylation at the major breakpoint region (MBR) CpG sites. We recently described an increased frequency of BCL2/ JH translocation with aging. It is known that methylation levels change with aging. The present study aimed to determine whether methylation alterations at CpG sites of BCL2 MBR were the cause of increased breakages with aging. We analyzed the methylation levels of three CpG sites on the region by pyrosequencing and studied if methylation levels and/or polymorphisms affecting CpG sites were associated with an increase of translocations. We observed that although the methylation levels of MBR CpG sites were higher in individuals with BCL2/JH translocation, in contrast to our expectations, these levels decreased with the age. Moreover, we show that polymorphisms at those CpG sites leading to absence of methylation seem to be a protective factor for the apparition of translocations.
- Published
- 2015
- Full Text
- View/download PDF
31. Genetic variants in miRNA processing genes and pre-miRNAs are associated with the risk of chronic lymphocytic leukemia.
- Author
-
Martin-Guerrero I, Gutierrez-Camino A, Lopez-Lopez E, Bilbao-Aldaiturriaga N, Pombar-Gomez M, Ardanaz M, and Garcia-Orad A
- Subjects
- Genotyping Techniques, Haplotypes genetics, Humans, MicroRNAs chemistry, Nucleic Acid Conformation, Polymorphism, Single Nucleotide genetics, Risk Factors, Genetic Predisposition to Disease, Genetic Variation, Leukemia, Lymphocytic, Chronic, B-Cell genetics, MicroRNAs genetics, RNA Processing, Post-Transcriptional genetics
- Abstract
Genome wide association studies (GWAS) have identified several low-penetrance susceptibility alleles in chronic lymphocytic leukemia (CLL). Nevertheless, these studies scarcely study regions that are implicated in non-coding molecules such as microRNAs (miRNAs). Abnormalities in miRNAs, as altered expression patterns and mutations, have been described in CLL, suggesting their implication in the development of the disease. Genetic variations in miRNAs can affect levels of miRNA expression if present in pre-miRNAs and in miRNA biogenesis genes or alter miRNA function if present in both target mRNA and miRNA sequences. Therefore, the present study aimed to evaluate whether polymorphisms in pre-miRNAs, and/or miRNA processing genes contribute to predisposition for CLL. A total of 91 SNPs in 107 CLL patients and 350 cancer-free controls were successfully analyzed using TaqMan Open Array technology. We found nine statistically significant associations with CLL risk after FDR correction, seven in miRNA processing genes (rs3805500 and rs6877842 in DROSHA, rs1057035 in DICER1, rs17676986 in SND1, rs9611280 in TNRC6B, rs784567 in TRBP and rs11866002 in CNOT1) and two in pre-miRNAs (rs11614913 in miR196a2 and rs2114358 in miR1206). These findings suggest that polymorphisms in genes involved in miRNAs biogenesis pathway as well as in pre-miRNAs contribute to the risk of CLL. Large-scale studies are needed to validate the current findings.
- Published
- 2015
- Full Text
- View/download PDF
32. Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis.
- Author
-
Rojas SM, Díez-Campelo M, Luño E, Cabrero M, Pedro C, Calabuig M, Nomdedeu B, Cedena T, Arrizabalaga B, García M, Cerveró C, Collado R, Azaceta G, Ardanaz MT, Muñoz JA, Xicoy B, Rodríguez MJ, Bargay J, Morell MJ, Simiele A, and del Cañizo C
- Subjects
- Adult, Aged, Aged, 80 and over, Anemia etiology, Anemia mortality, Anemia therapy, Antineoplastic Agents therapeutic use, Biomarkers, Tumor analysis, Disease Progression, Female, Humans, Lenalidomide, Male, Middle Aged, Multivariate Analysis, Myelodysplastic Syndromes complications, Myelodysplastic Syndromes drug therapy, Myelodysplastic Syndromes mortality, Prognosis, Retrospective Studies, Survival Analysis, Thalidomide analogs & derivatives, Thalidomide therapeutic use, Time Factors, Anemia diagnosis, Blood Transfusion statistics & numerical data, Chromosome Deletion, Chromosomes, Human, Pair 5, Myelodysplastic Syndromes diagnosis
- Abstract
Patients with isolated del(5q) and MDS are considered to have good prognosis as compared to other MDS subtypes. Most patients suffered of anemia and 50% of them required transfusions at diagnosis. It is known that for patients with MDS and del(5q) in transfusion dependence(TD), Lenalidomide is the first choice treatment. However, there are no data regarding natural evolution of anemia in patients diagnosed in MDS and del(5q) without TD, factors that may impact on the development of TD or disease outcome. In the present study we have performed a retrospective multicenter analysis on 83 patients with low-int 1 MDS and del(5q) without TD. During the study 61 patients became TD at a median of 1.7 years and only the Hb level 9 g/dL was associated with poorer TFS (p = 0.007) in the multivariate analysis. Among these 61 TD patients, 49 received treatment (19 Lenalidomide). Median follow up was 48 months, estimated OS at 2 and 5 year was 92% and 50% respectively. In the multivariate analysis for OS, platelets <100,000 mm(-3) and Lenalidomide treatment retained the statistical significant impact. LFS at 2 and 5 years was 86% and 73% respectively, and median time to sAML was 8.16 years (CI 95%: 6.05-10.27). In the multivariate analysis only thrombocytopenia retained statistical significance. In summary, this retrospective study show that level of Hb is an important parameter in order to determine the time until TD, it should be also stressed the importance of an early treatment in order to prevent TD development and shorter survival., (Copyright © 2013 Elsevier Ltd. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
33. Methylation of the nonhomologous end joining repair pathway genes does not explain the increase of translocations with aging.
- Author
-
Martín-Guerrero I, de Prado E, Lopez-Lopez E, Ardanaz M, Vitoria JC, Parada LA, García-Orad C, and García-Orad A
- Subjects
- Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Aging physiology, Chi-Square Distribution, Child, Child, Preschool, Cohort Studies, Confidence Intervals, DNA Breaks, Double-Stranded, Female, Humans, Infant, Male, Middle Aged, Odds Ratio, Polymerase Chain Reaction methods, Sensitivity and Specificity, Signal Transduction genetics, Young Adult, Aging genetics, DNA End-Joining Repair genetics, DNA Methylation genetics, Translocation, Genetic physiology
- Abstract
Chromosome translocations are especially frequent in human lymphomas and leukemias but are insufficient to drive carcinogenesis. Indeed, several of the so-called tumor specific translocations have been detected in peripheral blood of healthy individuals, finding a higher frequency of some of them with aging. The inappropriate repair of DNA double strand breaks by the nonhomologous end joining (NHEJ) pathway is one of the reasons for a translocation to occur. Moreover, fidelity of this pathway has been shown to decline with age. Although the mechanism underlying this inefficacy is unknown, other repair pathways are inactivated by methylation with aging. In this study, we analyzed the implication of NHEJ genes methylation in the increase of translocations with the age. To this aim, we determined the relationship between translocations and aging in 565 Spanish healthy individuals and correlated these data with the methylation status of 11 NHEJ genes. We found higher frequency of BCL2-JH and BCR-ABL (major) translocations with aging. In addition, we detected that two NHEJ genes (LIG4 and XRCC6) presented age-dependent promoter methylation changes. However, we did not observe a correlation between the increase of translocations and methylation, indicating that other molecular mechanisms are involved in the loss of NHEJ fidelity with aging.
- Published
- 2014
- Full Text
- View/download PDF
34. Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome.
- Author
-
Gonzalez-Porras JR, Cordoba I, Such E, Nomdedeu B, Vallespi T, Carbonell F, Luño E, Ardanaz M, Ramos F, Pedro C, Gomez V, de Paz R, Sanchez-Barba M, Sanz GF, and Del Cañizo AC
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Incidence, Male, Middle Aged, Myelodysplastic Syndromes epidemiology, Prognosis, Retrospective Studies, Risk Factors, Spain epidemiology, Survival Analysis, Thrombocytopenia epidemiology, Young Adult, Myelodysplastic Syndromes blood, Myelodysplastic Syndromes complications, Thrombocytopenia complications
- Abstract
Background: Thrombocytopenia is very common in myelodysplastic syndrome (MDS); however, its clinical impact in low-risk patients remains controversial., Methods: The authors analyzed the incidence and prognostic significance of thrombocytopenia at diagnosis in 2565 de novo MDS patients included in the Spanish MDS Registry., Results: Thrombocytopenia (platelet count <100 × 10(9) /L) was identified in 842 patients (32.8%). Severe thrombocytopenia (platelet count <30 × 10(9) /L) was observed in 7.1% of patients and was significantly associated with a higher-risk World Health Organization subtype (P = .026) and intermediate-2/high-risk International Prognostic Scoring System (IPSS) score (P = .046). Severe thrombocytopenia was the most important prognostic factor and had negative effects on the low/intermediate-1 risk group. Median overall survival of patients with a platelet count <30 and ≥ 30 × 10(9) /L was 16 months and 71 months, respectively (hazard ratio, 4.66; 95% confidence interval, 2.74-7.90; P < .0001). The negative effect of severe thrombocytopenia in low/intermediate-1 risk patients was caused by increased risk of bleeding., Conclusions: MDS patients with low/intermediate-1 IPSS risk score and severe thrombocytopenia should no longer be regarded as low risk, and must be considered for disease-altering approaches at diagnosis., (Copyright © 2011 American Cancer Society.)
- Published
- 2011
- Full Text
- View/download PDF
35. A putative "hepitype" in the ATM gene associated with chronic lymphocytic leukemia risk.
- Author
-
Martín-Guerrero I, Enjuanes A, Richter J, Ammerpohl O, Colomer D, Ardanaz M, Marco F, Salas A, Campo E, Siebert R, and García-Orad A
- Subjects
- Aged, Ataxia Telangiectasia Mutated Proteins, Case-Control Studies, Cell Cycle Proteins metabolism, Computer Simulation, DNA Methylation, DNA-Binding Proteins metabolism, Female, Genetic Predisposition to Disease, Haplotypes, Humans, Male, Middle Aged, Polymorphism, Single Nucleotide, Prognosis, Protein Serine-Threonine Kinases metabolism, RNA, Messenger genetics, Risk Factors, Tumor Suppressor Proteins metabolism, Cell Cycle Proteins genetics, DNA-Binding Proteins genetics, Leukemia, Lymphocytic, Chronic, B-Cell genetics, Protein Serine-Threonine Kinases genetics, Tumor Suppressor Proteins genetics
- Abstract
Chronic lymphocytic leukemia (CLL) cells are characterized by several chromosomal lesions. Some of these aberrations imply chromosome breaks as a result of unrepaired double strand breaks (DSBs) in the DNA. The ATM (ataxia telangiectasia-mutated) protein is the principal integrator of cellular responses to DSBs. ATM deletion is also an adverse prognostic factor in CLL. Taking this into account, we evaluated if genetic and/or epigenetic variation in the ATM gene may modulate the individual susceptibility to develop CLL. Our case-control association study was performed in a large Spanish population of 1,503 individuals, including 742 patients with CLL and 761 controls. We identified one haplotype within the ATM gene that confers an increased risk of CLL development (OR = 1.33; 95% CI: 1.10-1.60). Two polymorphisms of this ATM haplotype eliminated one CpG site each in Introns 15 and 61, causing changes in DNA methylation pattern. These data provide the first evidence for the existence of a putative "hepitype" in the ATM gene associated with CLL risk., (Copyright © 2011 Wiley-Liss, Inc.)
- Published
- 2011
- Full Text
- View/download PDF
36. High mitochondrial DNA stability in B-cell chronic lymphocytic leukemia.
- Author
-
Cerezo M, Bandelt HJ, Martín-Guerrero I, Ardanaz M, Vega A, Carracedo A, García-Orad A, and Salas A
- Subjects
- Base Sequence, DNA Primers genetics, Databases, Genetic, Granulocytes cytology, Haplotypes, Humans, Lymphocytes cytology, Models, Statistical, Molecular Sequence Data, Mutation, Phylogeny, Sequence Analysis, DNA, DNA, Mitochondrial genetics, Leukemia, Lymphocytic, Chronic, B-Cell genetics, Leukemia, Lymphocytic, Chronic, B-Cell metabolism
- Abstract
Background: Chronic Lymphocytic Leukemia (CLL) leads to progressive accumulation of lymphocytes in the blood, bone marrow, and lymphatic tissues. Previous findings have suggested that the mtDNA could play an important role in CLL., Methodology/principal Findings: The mitochondrial DNA (mtDNA) control-region was analyzed in lymphocyte cell DNA extracts and compared with their granulocyte counterpart extract of 146 patients suffering from B-Cell CLL; B-CLL (all recruited from the Basque country). Major efforts were undertaken to rule out methodological artefacts that would render a high false positive rate for mtDNA instabilities and thus lead to erroneous interpretation of sequence instabilities. Only twenty instabilities were finally confirmed, most of them affecting the homopolymeric stretch located in the second hypervariable segment (HVS-II) around position 310, which is well known to constitute an extreme mutational hotspot of length polymorphism, as these mutations are frequently observed in the general human population. A critical revision of the findings in previous studies indicates a lack of proper methodological standards, which eventually led to an overinterpretation of the role of the mtDNA in CLL tumorigenesis., Conclusions/significance: Our results suggest that mtDNA instability is not the primary causal factor in B-CLL. A secondary role of mtDNA mutations cannot be fully ruled out under the hypothesis that the progressive accumulation of mtDNA instabilities could finally contribute to the tumoral process. Recommendations are given that would help to minimize erroneous interpretation of sequencing results in mtDNA studies in tumorigenesis.
- Published
- 2009
- Full Text
- View/download PDF
37. [Foetal/neonatal alloimmune thrombocytopenia. A review and case report].
- Author
-
Rodríguez Wilhelmi P, Aranguren A, Muñiz E, Aranburu E, Ezpeleta I, Ardanaz MF, and Ayape ML
- Subjects
- Adult, Female, Humans, Immunoglobulins, Intravenous therapeutic use, Infant, Newborn, Intracranial Hemorrhages mortality, Intracranial Hemorrhages therapy, Platelet Count, Platelet Transfusion, Pregnancy, Intracranial Hemorrhages etiology, Thrombocytopenia, Neonatal Alloimmune diagnosis, Thrombocytopenia, Neonatal Alloimmune therapy
- Abstract
Foetal/neonatal alloimmune thrombocytopenia is the most common cause of severe thrombocytopenia in the newborn. It is an acute disorder which implies that foetal platelets are destroyed during the pregnancy due to a maternal alloimmune IgG antibody. More than 80% of Caucasians are HPA-1a specific. Intracranial haemorrhage, which occurs in 30% of cases, is the most serious complication, with a 10% mortality rate or a 20% rate of irreversible neurological sequels. The high risk of a recurrence of serious bleeding in future pregnancies led us to consider prophylaxis or prenatal treatment. An early diagnosis of this process allows an effective therapy to be carried out based on the infusion of compatible phenotype HPA platelets or endovenous immunoglobulins. We present the case of a 27 year old pregnant woman, who in the 35th week of a second pregnancy was diagnosed using echography with a bilateral foetal hydrocephaly. After caesarean delivery in the 36th week, the newborn presented haematomas in the left shoulder and gluteus, macrocephalia with tension of the fontanellas and hemorrhagic cerebrospinal fluid after insertion of an external ventricular derivation catheter. The haemogram revealed a severe trombocytopenia (9 x 109/L). In the light of clinical suspicion of foetal/neonatal alloimmune thrombocytopenia, infusion was made of platelets from a non-phenotyped donor for the HPA-1a system, and an endovenous immunoglobulin treatment was followed, with a recovery of platelet counts, but with neurological sequels that are probably irreversible. The immunohaematologal study confirmed the negative HPA-1a maternal phenotype, the neonatal HPA-1a positive phenotype and the presence of anti-HPA-1a alloantibodies in the maternal serum. Nowadays, the prophylaxis and treatment continue to be a controversial issue that is open to discussion, as is the possibility of implementing antenatal screening.
- Published
- 2008
- Full Text
- View/download PDF
38. Macrophage activation syndrome as the initial manifestation of systemic onset juvenile idiopathic arthritis.
- Author
-
Cuende E, Vesga JC, Pérez LB, Ardanaz MT, and Guinea J
- Subjects
- Anti-Inflammatory Agents therapeutic use, Antirheumatic Agents therapeutic use, Arthritis, Juvenile drug therapy, Arthritis, Juvenile pathology, Child, Preschool, Humans, Immune System Diseases drug therapy, Immune System Diseases pathology, Macrophage Activation immunology, Male, Methotrexate therapeutic use, Methylprednisolone therapeutic use, Syndrome, Treatment Outcome, Arthritis, Juvenile complications, Immune System Diseases etiology
- Published
- 2001
39. Hypodiploidy and 22q11 rearrangements at diagnosis are associated with poor prognosis in patients with multiple myeloma.
- Author
-
Calasanz MJ, Cigudosa JC, Odero MD, García-Foncillas J, Marín J, Ardanaz MT, Rocha E, and Gullón A
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Gene Rearrangement, Humans, Karyotyping, Male, Middle Aged, Prognosis, Chromosome Aberrations, Diploidy, Multiple Myeloma genetics
- Abstract
Our aim was to evaluate the clinical use of cytogenetic analysis as a prognostic factor in the outcome of newly diagnosed multiple myeloma (MM) patients. The present series includes 111 newly diagnosed MM patients treated with one of three standard-dose regimens or autologous transplantation over an 8-year time interval. As expected, the presence of an abnormal karyotype (39% of patients) correlated with poor prognosis (progression rate 63% v 47%, P = 0.042), shorter event-free (EFS, P = 0.014) and overall (OS, P = 0.005) survival. Two distinct cytogenetic abnormalities were the most significant variables that influenced EFS and OS in the univariate analysis. The presence of hypodiploid karyotypes or rearrangements of band 22q11 were associated with higher progression rate (P = 0.001) and shorter EFS (P < 0.024) and OS (P < 0.004). The median EFS and OS for patients with hypodiploidy was 4 and 7 months respectively. Multivariate analysis showed that absence of hypodiploidy was the most favourable prognostic variable for OS (P = 0.022) followed by stage < or = IIA, serum calcium < or = 2875 micromol/l, and absence of abnormalities 22q. The data suggest that the presence of hypodiploid karyotypes and rearrangements on 22q11 band show a higher progression rate and shorter survival in MM patients.
- Published
- 1997
- Full Text
- View/download PDF
40. [National network of phenotyped erythrocytes: report on the current situation].
- Author
-
Aranburu E, Ayape ML, Ardanaz MF, Esquiroz P, and Medarde A
- Subjects
- Blood Transfusion statistics & numerical data, Forms and Records Control, Health Services Needs and Demand, Humans, Immunophenotyping, Interinstitutional Relations, Spain, Blood Banks organization & administration, Blood Group Antigens immunology, Erythrocytes immunology
- Published
- 1997
41. [Hemoglobin in blood donor selection].
- Author
-
Chueca PM, Galar GM, Ardanaz MF, Zabalegui A, Muruzábal L, and Muñoz A
- Subjects
- Adult, Female, Ferritins blood, Humans, Iron blood, Male, Middle Aged, Predictive Value of Tests, Sensitivity and Specificity, Blood Donors statistics & numerical data, Hemoglobins analysis
- Abstract
Purpose: To evaluate and establish a relationship between serum ferritin value and haemoglobin level, serum iron or transferrin in volunteer blood donors., Material and Methods: We have studied a group of 479 blood donors from Navarra's Health Area V, whose blood cell examination, iron, ferritin and transferrin values were determined. We classified these donors in 4 groups according to their ferritin concentration (ng/mL): f1 (0-12), f2 (13-20), f3 (21-400) and f4 (more than 400). The results were analyzed by the statistical program SPSS/PC+. The sensitivity, specificity, accuracy and predictive value of the positive test, for the determination of haemoglobin level as an indicator of iron deposits were calculated., Results: The comparative statistical study of all these groups indicated that there were significant differences in the ferritin and the haemoglobin values (p < 0.001 and p < 0.05, respectively), except between f1 and f2, which only presented and intergroup difference in the ferritin values. In blood donors, the estimation of iron deposits from the hemoglobin level showed a diagnostic sensitivity greater than 90%., Conclusions: Haemoglobin values would allow the selection of those donors that could have an iron deficiency, or a borderline concentration; nevertheless, it would not allow the distinction between these two groups. This last observation is not important because donors that show a ferritin value lower than 20 ng/mL should not give blood. When the ferritin is greater than 20 ng/mL in men, the iron deposits will be adequate in 97% of them. This percentage is about 90 in women whose haemoglobin level is greater than 12.5 g/dL. Therefore, we consider that haemoglobin values present a good cost/benefit ratio for donor selection.
- Published
- 1995
42. [Persistent monocytosis associated with chronic lymphatic leukemia].
- Author
-
Diego MJ, Menchaca C, Araiz M, and Ardanaz MT
- Subjects
- Aged, Aged, 80 and over, Female, Hematologic Diseases pathology, Humans, Hematologic Diseases etiology, Leukemia, Lymphocytic, Chronic, B-Cell complications, Monocytes
- Published
- 1995
43. Complex karyotype including trisomy 8 in a case of B-chronic lymphocytic leukemia.
- Author
-
Cruz Cigudosa J, Jose Calasanz M, Gullon A, and Ardanaz MT
- Subjects
- Aged, Chromosomes, Human, Pair 16, Chromosomes, Human, Pair 2, Humans, Karyotyping, Male, Translocation, Genetic genetics, Chromosomes, Human, Pair 8, Leukemia, Lymphocytic, Chronic, B-Cell genetics, Trisomy
- Published
- 1992
- Full Text
- View/download PDF
44. [Homozygous Pelger-Huët anomaly. Apropos of a case].
- Author
-
Gastearena J, Orue MT, Pérez Equiza E, Hernández MC, Ardanaz MF, and Uriz MJ
- Subjects
- Blood Sedimentation, Bone Marrow pathology, Child, Genotype, Granulocytes physiology, Humans, Leukocytes pathology, Male, Pelger-Huet Anomaly blood, Pelger-Huet Anomaly genetics
- Published
- 1982
45. [Transient erythroleukemia in the development of acute monocytic leukemia in Fanconi's anemia].
- Author
-
Gastearena J, Orue MT, Pérez Equiza E, Calderón F, Ardanaz MF, Hernández MC, and Uriz MJ
- Subjects
- Child, Fanconi Anemia blood, Fanconi Anemia pathology, Humans, Male, Time Factors, Anemia, Aplastic complications, Fanconi Anemia complications, Leukemia, Erythroblastic, Acute etiology, Leukemia, Monocytic, Acute etiology
- Published
- 1982
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.